Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Pulmatrix Inc (PULM)

Pulmatrix Inc (PULM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine PR Newswire - Tue Sep 19, 2023

/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...

PULM : 2.20 (+3.77%)
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole PR Newswire - Wed Aug 23, 2023

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious...

PULM : 2.20 (+3.77%)
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update PR Newswire - Thu Aug 10, 2023

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...

PULM : 2.20 (+3.77%)
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine PR Newswire - Tue Jul 11, 2023

/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...

PULM : 2.20 (+3.77%)
Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society PR Newswire - Thu Jun 15, 2023

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...

PULM : 2.20 (+3.77%)
Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention PR Newswire - Wed May 24, 2023

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...

PULM : 2.20 (+3.77%)
Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update PR Newswire - Fri May 12, 2023

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...

PULM : 2.20 (+3.77%)
Pulmatrix Supports World Asthma Day 2023 PR Newswire - Tue May 2, 2023

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...

PULM : 2.20 (+3.77%)
Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update PR Newswire - Thu Mar 30, 2023

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...

PULM : 2.20 (+3.77%)
Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment" PR Newswire - Wed Jan 25, 2023

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease...

PULM : 2.20 (+3.77%)

Barchart Exclusives

Talen Energy - Nuclear. Fossil, Solar And Coal All In One Package Barchart - 3 minutes ago
Summary Talen Energy (TLN) shows strong technical indicators with 100% buy signals, a 247.38+ Weighted Alpha, and a 218.06% gain in the last year. The company operates 10.7 GW of power infrastructure, including nuclear, fossil, solar, and coal plants, and is developing battery storage projects. Wall Street analysts are bullish... Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot